Pharmacological modulation of prostaglandin E2 (PGE2) EP receptors improves cardiomyocyte function under hyperglycemic conditions

Pharmacological modulation of prostaglandin E2 (PGE2) EP receptors improves cardiomyocyte function under hyperglycemic conditions

Abstract Type 2 diabetes (T2D) affects >30 million Americans and nearly 70% of individuals with T2D will die from cardiovascular disease (CVD). Circulating levels of the inflammatory signaling lipid, prostaglandin E2 (PGE2), are elevated in the setting of obesity and T2D and are associated with d...

Full description

Bibliographic Details
Main Authors: Karin J. Bosma, Monica Ghosh, Spencer R. Andrei, Lin Zhong, Jennifer C. Dunn, Valerie F. Ricciardi, Juliann B. Burkett, Antonis K. Hatzopoulos, Derek S. Damron, Maureen Gannon
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Physiological Reports
Subjects:
contractility
diabetic cardiomyopathy
ejection fraction
prostaglandin receptor
Type 2 diabetes
Online Access:https://doi.org/10.14814/phy2.15212

Internet

https://doi.org/10.14814/phy2.15212

Similar Items